Aspiriant LLC’s Biogen BIIB Stock Holding History

Aspiriant LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-848	Closed	-$246K	–	241
2018 Q2	$246K	Buy	+848	New	+$238K	0.02%	221

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Aspiriant LLC's BIIB Position: Q3 2018 in Review

Aspiriant LLC sold out of Biogen (BIIB) in Q3 2018, closing a stake of 848 shares — an estimated $246K sold.

Aspiriant LLC first reported a position in BIIB in Q2 2018 and held it in 1 quarter. The position peaked at $246K in Q2 2018. 1,145 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

Aspiriant LLC reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
Aspiriant LLC sold 848 Biogen shares in Q3 2018, an estimated $246K.
Aspiriant LLC first reported a position in Biogen in Q2 2018 and held it in 1 quarter.
Aspiriant LLC's Biogen position peaked at $246K in Q2 2018.
1,145 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Aspiriant LLC's 13F filing for Q3 2018, filed 26 Oct 2018.